Page 252 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
EGFR and PIK3CA mutations in lung cancer patients

non-small cell lung cancer. Tumori. 2021;107(4):335-340. 33. Zhang L, Shi L, Zhao X, Wang Y, Yue W. PIK3CA
gene mutation associated with poor prognosis of lung
doi: 10.1177/0300891620964571
adenocarcinoma. Onco Targets Ther. 2013;6:497-502.
24. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung doi: 10.2147/OTT.S41643
cancer: Correlation with clinical response to Gefitinib
therapy. Science. 2004;304(5676):1497-1500. 34. Wang Y, Wang Y, Li J, Li J, Che G. Clinical significance
of PIK3CA gene in non-small-cell lung cancer:
doi: 10.1126/science.1099314
A systematic review and meta-analysis. Biomed Res Int.
25. Hayes TK, Aquilanti E, Persky NS, et al. Comprehensive 2020;2020:3608241.
mutational scanning of EGFR reveals TKI sensitivities doi: 10.1155/2020/3608241
of extracellular domain mutants. Nat Commun.
2024;15(1):2742. 35. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase
mutations identified in human cancer are oncogenic. Proc
doi: 10.1038/s41467-024-45594-4. Erratum in: Nat Natl Acad Sci U S A. 2005;102(3):802-807.
Commun. 2024;15(1):3273.
doi: 10.1073/pnas.0408864102
doi: 10.1038/s41467-024-47675-w
36. Zeller KS, Idevall-Hagren O, Stefansson A, et al. PI3-kinase
26. Boukansa S, Mouhrach I, El Agy F, et al. Clinicopathological p110α mediates β1 integrin-induced Akt activation and
and prognostic implications of EGFR mutations subtypes in membrane protrusion during cell attachment and initial
Moroccan non-small cell lung cancer patients: A first report. spreading. Cell Signal. 2010;22(12):1838-1848.
PLoS One. 2024;19(6):e0298721.
doi: 10.1016/j.cellsig.2010.07.011
doi: 10.1371/journal.pone.0298721
37. Chen H, Gao W, Liu H, Sun B, Hua C, Lin X. Updates on
27. Morjani O, Benkirane N, Errihani H, Elfahime EM, diagnosis and treatment of PIK3CA-related overgrowth
Lakhiari H. Molecular analysis of genetic mutations in spectrum. Ann Plast Surg. 2023;90:S209-S215.
non-small cell lung cancer in Morocco. Pan Afr Med J.
2024;47:116. doi: 10.1097/SAP.0000000000003389
doi: 10.11604/pamj.2024.47.116.42973 38. Scheffler M, Bos M, Gardizi M, et al. PIK3CA mutations in
non-small cell lung cancer (NSCLC): Genetic heterogeneity,
28. Da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations prognostic impact and incidence of prior malignancies.
and lung cancer. Annu Rev Pathol. 2011;6:49-69. Oncotarget. 2015;6(2):1315-1326.
doi: 10.1146/annurev-pathol-011110-130206 doi: 10.18632/oncotarget.2834
29. Patel SR, Neal JW. Adjuvant Osimertinib for resected EGFR- 39. Rosell R, Karachaliou N. Co-mutations in EGFR driven
mutated non-small cell lung cancer: A game-changer? Transl non-small cell lung cancer. EBioMedicine. 2019;42:18-19.
Lung Cancer Res. 2023;12(7):1631-1635.
doi: 10.1016/j.ebiom.2019.03.037
doi: 10.21037/tlcr-23-273
40. Peters S, Zimmermann S. Targeted therapy in NSCLC driven
30. Shi R, Li M, Raghavan V, et al. Targeting the CDK4/6-Rb by HER2 insertions. Transl Lung Cancer Res. 2014;3(2):84-88.
pathway enhances response to PI3K inhibition in PIK3CA-
mutant lung squamous cell carcinoma. Clin Cancer Res. doi: 10.3978/j.issn.2218-6751.2014.02.06
2018;24(23):5990-6000. 41. Cheng X. A comprehensive review of HER2 in cancer
doi: 10.1158/1078-0432.CCR-18-0717 biology and therapeutics. Genes (Basel). 2024;15(7):903.
31. Wang M, Li J, Huang J, Luo M. The predictive role of PIK3CA doi: 10.3390/genes15070903
mutation status on PI3K inhibitors in HR+ breast cancer 42. Elghissassi I, Inrhaoun H, Boukir A, et al. Frequency and
therapy: A systematic review and meta-analysis. Biomed Res spectrum of KRAS mutations in moroccan patients with
Int. 2020;2020:1598037. lung adenocarcinoma. ISRN Oncol. 2014;2014:192493.
doi: 10.1155/2020/1598037 doi: 10.1155/2014/192493
32. Alqahtani A, Ayesh HSK, Halawani H. PIK3CA gene 43. Arcila ME, Chaft JE, Nafa K, et al. Prevalence,
mutations in solid malignancies: Association with clinicopathologic associations, and molecular spectrum
clinicopathological parameters and prognosis. Cancers of ERBB2 (HER2) tyrosine kinase mutations in lung
(Basel). 2019;12(1):93. adenocarcinomas. Clin Cancer Res. 2012;18(18):4910-4918.
doi: 10.3390/cancers12010093 doi: 10.1158/1078-0432.CCR-12-0912

Volume 9 Issue 1 (2025) 244 doi: 10.36922/ejmo.7111